SugenTech Inc
KOSDAQ:253840
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| KR |
S
|
SugenTech Inc
KOSDAQ:253840
|
76.4B KRW |
Loading...
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
190.9B USD |
Loading...
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
171.7B USD |
Loading...
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
133.7B USD |
Loading...
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
113.2B USD |
Loading...
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
103.5B USD |
Loading...
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
43.3B EUR |
Loading...
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
48.5B USD |
Loading...
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
46.7B USD |
Loading...
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
45.6B USD |
Loading...
|
|
| US |
|
Resmed Inc
NYSE:RMD
|
33.6B USD |
Loading...
|
Market Distribution
| Min | -646.5% |
| 30th Percentile | 12.8% |
| Median | 19.7% |
| 70th Percentile | 32.2% |
| Max | 54 001.3% |
Other Profitability Ratios
SugenTech Inc
Glance View
Sugentech, Inc. develops in-vitro diagnostic systems and products. The company is headquartered in Daejeon, Daejeon. The company went IPO on 2016-11-11. The firm is involved in the manufacturing and sale of in vitro diagnostic test reagents, point-of-care testing (POCT) products, folic acid products under the name of SOLGAR, as well as molecular diagnostic reagents. The in vitro diagnostic test reagents are for personal use and are sold under the name SUREARLY. The POCT products are for professional use and are sold under the name INCLIX. In addition, the Company is engaged in therapeutic drug monitoring, as well as drug analysis method development. The firm distributes its products within the domestic market and to overseas markets, including Indonesia.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for SugenTech Inc is -5.7%, which is above its 3-year median of -62.1%.
Over the last 3 years, SugenTech Inc’s Gross Margin has decreased from 65.2% to -5.7%. During this period, it reached a low of -374.1% on Sep 30, 2023 and a high of 65.2% on Sep 30, 2022.
